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Abstract: Because of the recognized health benefits of breast milk, it is recommended as the sole
nutrition source during the first 6 months of life. Among the bioactive components are human milk
oligosaccharides (HMOs) that exert part of their activity via the gut microbiota. Here, we investigated
the gut microbiota fermentation of HMO 2’fucosyllactose (2’-FL), using two in vitro models (48 h
fecal incubations and the long-term mucosal simulator of the human intestinal microbial ecosystem
[M-SHIME®]) with fecal samples from 3-month-old breastfed (BF) infants as well as 2–3 year old
toddlers. The short-term model allowed the screening of five donors for each group and provided
supportive data for the M-SHIME® study. A key finding was the strong and immediate increase
in the relative abundance of Bifidobacteriaceae following 2’-FL fermentation by both the BF infant
and toddler microbiota in the M-SHIME®. At the metabolic level, while decreasing branched-chain
fatty acids, 2’-FL strongly increased acetate production together with increases in the health-related
propionate and butyrate whilst gas production only mildly increased. Notably, consistently lower gas
production was observed with 2’-FL fermentation as compared to lactose, suggesting that reduced
discomfort during the dynamic microbiome establishment in early life may be an advantage along
with the bifidogenic effect observed.
Keywords: 2’fucosyllactose; human milk oligosaccharides; infant gut microbiota; lactose; mucosal
simulator of the human intestinal microbial ecosystem; prebiotic; toddler gut microbiota
1. Introduction
Gut microbes play a key role in human health, including the development of the
immune system [1–3] and host metabolism [4,5]. Gut microbiome fermentation of indi-
gestible dietary glycans into short-chain fatty acids (SCFAs); mostly acetate, propionate,
and butyrate, are important in maintaining host health throughout life [6]. In terms of com-
position, infants have a less diverse gut microbial community with a lower representation
of members of Bacteroidetes, Firmicutes, and Archaea compared with adults [7,8]. In contrast,
the infant gut microbial community is dominated by members of the Bifidobacteriaceae
family [7], which are specialized to ferment carbohydrates derived from breast milk into
acetate and lactate [9]. This Bifidobacteriaceae dominance persists during the first year of
life, followed by a decreased relative percentage as the infant ages [7,10]. The gut microbial
community continues to change and becomes more diverse and adult-like by age three [7].
With increasing age, cross-feeding bacteria (such as acetate and/or lactate converters) begin
to more heavily colonize the gut, resulting in an increased production of propionate and
butyrate [11,12]. As the microbial community evolves, members of the Bacteroidetes and
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Firmicutes phylum eventually comprise approximately 90% of the gut microbiota [8,13].
Both gas production and pH can fluctuate depending upon the composition of the gut
microbial community [14,15]. pH can affect community diversity and the production of
SCFAs [14], and therefore the effects of active substances on pH are important to consider.
Additionally, Gas production can lead to discomfort, so active substances that ultimately
result in reduced gas production are desirable. While in vivo studies have provided inter-
esting knowledge and are key to prove the final efficacy of an active agent, they are often
rather descriptive and do not allow for the gleaning of insights into the mechanisms by
which specific glycans affect the gut microbiota, leaving a clear need for well-controlled
in vitro studies to address such questions.
Breastfeeding is related to numerous benefits for the mother and infant [16–18]. Several
decades of research have shown that breast milk contains a variety of immunomodulatory,
anti-inflammatory, and antimicrobial substances that help to reduce short- and long-term
morbidity risks and positively influence the child’s cognitive and psychomotor develop-
ment [19–21]. As a result of the numerous benefits of breastfeeding, the World Health
Organization (WHO) recommends exclusive breastfeeding up to 6 months of age, with
continued breastfeeding along with appropriate complementary foods up to two years of
age and beyond [22,23].
Among the many bioactives found in human breast milk is a large amount and di-
versity of carbohydrates, namely the milk sugar lactose, and elongations of lactose by the
building blocks fucose, sialic acid, lacto-N-biose, and N-acetyl-lactosamine that are gen-
erally summarized as human milk oligosaccharides (HMOs) [24]. Concluded from basic
research, HMOs are expected to act via different routes including the support of growth and
metabolic activity of specific gut bacterial taxa such as specific bifidobacteria [25]. Among
the HMOs shown to modulate specific bifidobacteria is 2’fucosyllactose (2’-FL) [26–28].
2’-FL is a trisaccharide composed of L-fucose, D-galactose, and D-glucose units. Although
>150 different HMOs are described, the 20-30 HMOs that are generally quantified in dif-
ferent studies likely correspond to the vast majority by mass, and 2’FL is generally the
most abundant HMO in breast milk [29,30]. It is one of the HMOs available today in
large quantities from synthetic production and it is shown to be safe and beneficial for
infant nutrition [31–36]. Studies have shown that the addition of either 2’-FL alone or
2’-FL in combination with Lacto-N-neotetraose (LNnT; another HMO) to infant formula
supports immune and gut health [31,35,37]. 2’-FL is a trisaccharide composed of L-fucose,
D-galactose, and D-glucose units. While 2’-FL has shown potential for improving the health
of formula-fed infants, little is known about the mechanisms by which these improvements
are accomplished. Further, beyond the first few months of age there is currently a lack of
knowledge on possible roles of 2’-FL or other HMOs for toddlers who may still get HMOs
if breastfeeding is continued. To what extent recent observations of HMO supplementation
in adults can inform possible roles in toddlers has to be evaluated experimentally [38,39].
The gut microbiota composition varies largely among individuals [7,40]. This is the
case not only for adults, but also for infants and toddlers [7,41,42]. In fact, variation
between human individuals is reported to be greater among children (0–3 years of age)
than adults [7]. This can be explained by a multitude of factors such as vaginal versus
cesarean section delivery, breast milk versus formula feeding, or the use of antibiotics,
all factors that can impact the early colonization and subsequent development of the gut
ecosystem [43]. As these factors result in different microbial community composition, they
can thus also affect the utilization of dietary glycans [44,45]. Careful consideration of these
inter-individual differences among infants is thus needed when studying the effects of
dietary glycans on their gut microbiome.
Therefore, the current study was conducted to address the lack of understanding
of how 2’-FL affects the gut microbiome in infants and toddlers, while taking interindi-
vidual differences in gut microbiota composition into consideration. In the first part, we
applied our recently developed short-term in vitro fermentation model [46] to study the
effect of a single dose of 2’-FL versus lactose on gut microbiota from five breastfed (BF)
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infants (3 months old) and five toddlers (2 years old). The assessment involved parameters
related to microbial activity and Bifidobacterium levels. This donor screening allowed for the
selection of one representative donor from each age group for the second part of the study
that considered a more in-depth investigation of the effects of repeated intake of 2’-FL and
lactose over a period of 3 weeks on the gut microbiota using the mucosal simulator of
the human intestinal microbial ecosystem (M-SHIME®). This model simulates both longi-
tudinal differences (proximal versus distal colon) as well as differences between luminal
and mucosal microbiota [47]. Besides assessing microbial activity, microbial community
composition was assessed via 16S-targeted Illumina sequencing.
2. Materials and Methods
2.1. Test Products
All chemicals were obtained from Merck (Darmstadt, Germany) unless stated oth-
erwise. 2’-FL used in this study was provided by Glycom A/S (Horsholm, Denmark;
purity > 94% (w/w)), while lactose was acquired from Oxoid (Aalst, Belgium).
2.2. Experimental Design of Short-Term Incubations (Part 1) and Long-Term M-SHIME® Study
(Part 2)
The first part of the study considered short-term fecal batch incubations of a single
dose (5 g/L) of 2’-FL and lactose versus a blank control, when administered to a fecal
microbiota from five different BF infants (3 months old; D1–5) and five toddlers (2–3 years
old; D6-10), resulting in 30 independent reactors (Figure 1A). The incubation approach
was identical to the one recently described [46], with the following modifications: colonic
background medium (K2HPO4 4.8 g/L; KH2PO4 14.9 g/L; NaHCO3 2.0 g/L; yeast extract
2.0 g/L; peptone 2.0 g/L; mucin 1.0 g/L; cysteine 0.5 g/L; polyoxyethylene (20) sorbitan
monooleate 2.0 mL/L), and anaerobic phosphate buffer (K2HPO4 8.8 g/L; KH2PO4 6.8 g/L;
sodium thioglycolate 0.1 g/L; sodium dithionite 0.015 g/L). Samples were collected at
0 h, 24 h, and 48 h for microbial metabolic activity analysis: pH, Gas production, SCFA,
lactate, and branched-chain fatty acid (BCFA) production. At 48 h, Bifidobacterium levels
were quantified via qPCR.
The second part of the study considered assessing the effects of repeated intake of 2’-
FL and lactose on the gut microbiota using the M-SHIME® (ProDigest and ghent University,
Ghent, Belgium) (Figure 1B).
The configuration of the model parameters were adapted from the model for human
adults as described by Van den Abbeele et al. (2019) [47] to represent the gastrointestinal
tract of 3-month-old infants, as reported in De Boever et al. (2001) [48], with additional
minor adaptations for the simulation of approximately 2–3 year old toddlers as specified
below. This semi-continuous model allowed for the parallel investigation of four different
arms consisting of the two age groups (BF infant and toddler) and two treatments (2’-FL
and lactose) in a single setup consisting of 12 reactors (so-called QUAD-M-SHIME).Each
arm consisted of a first reactor that simulated over time the stomach and small intestine
and that operated according to a fill-and-draw principle, with peristaltic pumps adding
a defined amount of nutritional medium (140 mL) to the stomach at pH 3 and after 1.5 h
incubation followed by addition of pancreatic and bile liquid (60 mL) in the small intestine
(pH 6). After another 1.5 h incubation in the small intestine, the intestinal suspension
was pumped to the second and third reactors that simulated the proximal colon (PC) and
distal colon (DC). These reactors were continuously stirred with constant volume (300
mL in PC and 500 mL in DC) and pH control (pH 5.8–6.0 in PC and pH 6.0–6.5 in DC),
resulting in a total colonic retention time of 32 h. Each colonic reactor included a simulation
of the mucosal environment by the inclusion of mucin-coated microcosms as described
by Van den Abbeele et al. (2013) [49]. Reactor feed composition for the simulation of
BF infants consisted of 4 g/L mucin, 1 g/L yeast extract, 0.2 g/L cysteine, and around
10 g/L digested milk fragments (4.8 g/L lactose, 0.5 g/L casein, and 4.6 g/L lactalbumine).
For the simulation of a toddler microbiota, the digested milk fragments were decreased
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by half and replaced by carbohydrates to simulate the intake of solid food, i.e., 2 g/L starch,
1 g/L pectin, 1 g/L glucose, 1 g/L cellobiose. For both age groups, the pancreatic and
bile liquid consisted of 2.5 g/L NaHCO3, 0.9 g/L pancreatin and 4 g/L oxgall. The fecal
inoculum was prepared as described above with 20% (w/v) as compared to part 1. After
inoculating 5% (v/v) in the colonic reactors, the experiment was initiated. The SHIME®
cabinet and integrated software were run according to the manufacturer’s instructions
(ProDigest, Ghent, Belgium). The experimental timeline of the M-SHIME run consisted of a
two-week stabilization period (d-14 to d0), during which the fecal microbiota differentiated
to communities representative for a specific colon region, followed by a two-week baseline
period (d0 to d14) and a three-week treatment period (d14 to d35).




Figure 1. Schematic representation of the experimental set up: (A) Short-term incubations (part 1) to screen fecal samples 
from five BF infant and five toddler donors (48 h); (B) Long-term M-SHIME® study (part 2) using the selected fecal samples 
from the screening of a single BF infant and toddler donor, respectively (7 weeks). 2’-FL = 2’fucosyllactose; BF = breastfed; 
SFCA = short-chain fatty acid; BCFA = branched-chain fatty acid; ST/SI = stomach/small intestine; PC = proximal colon; 
DC = distal colon; M-SHIME® = mucosal simulator of the human intestinal microbial ecosystem. 
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DC = distal colon; M-SHIME® = mucosal simulator of the human intestinal microbial ecosystem.
During the treatment period, 2’-FL and lactose were administered at 10 g/L in the
nutritional medium resulting in a concentration of 7 g/L in the small intestinal suspension
that enters the proximal colon. Gas production and composition were assessed during the
M-SHIME® experiment using an offline setup that involved collecting samples from the
proximal colon and subsequently treating them with lactose or 2’-FL in closed reactors
for 48 h. This incubation strategy was identical to the one in the first part of the study
(short-term incubations) except for the inoculum that was derived from the M-SHIME®
model (7 mL), while in the first part of the study, it involved adding 1 mL fecal slurry. The
offline gas formation assessment was performed on samples collected before (d14) and
after treatment (d35) to assess whether repeated administration of 2’-FL or lactose in the
M-SHIME® resulted in altered gas production by the microbiota.
Mucosal and luminal samples were obtained at the same time point in each reactor
for microbiota analysis.
2.3. Microbial Community Analysis by qPCR
Samples collected after 48 h during the short-term incubations were evaluated for
the total amount of Bifidobacterium species by qPCR. DNA was isolated as described
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before [50] with minor modifications [51] from either 1 mL luminal samples or 0.1 g mucus
samples. Subsequently, qPCR was performed using a QuantStudio 5 Real-Time PCR system
(Applied Biosystems, Foster City, CA, USA). Each sample was run in technical triplicate
and outliers with more than 1 CT difference were omitted. The qPCRs were performed as
described previously with the primers Bif243F (5′-TCGCGTCYGGTGTGAAAG-3′) and
Bif243R (5′CCACATCCAGCRTCCAC-3′) [52]. Results are reported as log(16S rRNA gene
copies/mL).
2.4. Microbial Community Analysis by 16S rRNA Gene Sequencing
Microbial community composition was assessed before (d14) and after treatment
with 2’-FL and lactose (d16, d26, and d35). Samples were sent out to LGC Genomics
GmbH (Berlin, Germany) for next-generation 16S rRNA gene amplicon sequencing of the
V3–V4 region. Library preparation and sequencing were performed using an Illumina
MiSeq platform with v3 chemistry. The 341F (5′-CCTACGGGNGGCWGCAG-3′) and 785R
(5′-GACTACHVGGGTATCTAAKCC-3′) primers were used as previously described [53],
with the reverse primer being adapted to increase coverage. Quality control PCR was
conducted using Taq DNA Polymerase with the Fermentas PCR Kit according to the
manufacturers’ instructions (Thermo Fisher Scientific, Waltham, USA). The DNA quality
was verified by electrophoresis on a 2% (w/v) agarose gel for 30 min at 100 V. Bioinformatics
analysis of amplicon data was performed as previously [54]. Briefly, The mothur software
package (v.1.33.3) and guidelines were used to process the amplicon data generated by
LGC genomics. In short, after assembling forward and reverse reads, contigs with a
length between 441 and 467 bases were aligned to the mothur formatted silva_seed release
119 alignment database, trimmed between positions 6388 and 25316, to be compatible
with the 341F/785R primers [55]. After removing non-aligning sequences as well as
sequences containing homopolymer stretches of more than 12 bases, sequences were pre-
clustered, allowing up to 4 differences. UCHIME was applied to remove chimera [56].
Subsequently, sequences were classified, by means of a naive Bayesian classifier, against the
RDP 16S rRNA gene training set, version 14, with an 80% cut-off for the pseudobootstrap
confidence score. All sequences that were classified as Eukaryota, Archaea, Chloroplasts,
and Mitochondria were removed and only bacterial sequences were retained. Also, if
sequences could not be classified at all (even at (super)Kingdom level) they were removed.
Sequences were binned into Operational Taxonomic Units (OTU’s) within each order
identified by the preceding classification step. An OTU is defined in this manuscript as
a collection of sequences with a length between 402 and 427 nucleotides that are found
to be more than 97% similar to one another in the V3-V4 region of their 16S rRNA gene
after applying Opticlust clustering [57–60]. Taxonomy was assigned using the RDP version
16 and silva.nr_v123 database [56–58]. The shared file, containing the number of reads
observed for each OTU in each sample, was loaded into Microsoft® Excel® 2016 MSO
(16.0.11901.20070) (Redmond, USA). Reads occurring only 5 times in all samples were
removed, as they were supposedly artefacts or bacteria that were not having any biological
impact. For the most abundant OTUs, the sequences retrieved from 3% dissimilarity
level fasta file obtained in mothur were classified through the RDP web interface using
the RDP SeqMatch tool. The database search was restricted to type strains with only
near-full-length and good quality sequences. The sequences were blasted in NCBI against
the 16S rRNA gene sequences, selecting only type material, with optimization of the
BLAST algorithm for highly similar sequences (accession date: December 2018) [56,58,59].
Although identification to the species level based on short 300 bp reads may involve some
ambiguity, the most likely species classification of a few interesting OTUs is reported in
the results sections. In the event of inconsistencies in the results of the RDP SeqMatch tool
and NCBI BLAST, no species level classification is provided. The results are presented
as proportional values. Diversity indices (Shannon, Chao1), evenness, and richness were
calculated using Calypso software version 8.72 [61].
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2.5. Metabolic Analysis
pH measurements were performed using a Senseline pH meter F410 (ProSense, Oost-
erhout, The Netherlands). Gas formation was measured using a pressure meter to which a
needle was connected (hand-held pressure indicator CPH6200; Wika, Echt, The Nether-
lands). Gas-phase composition was analyzed using a compact gC (Global Analyser Solu-
tions, Breda, The Netherlands), equipped with a Molsieve 5A pre-column and Porabond
column (for CH4, O2, H2, N2), a Rt-Q-bond pre-column, and column (for CO2, N2O, and
H2S), and a thermal conductivity detector. The parameters used to evaluate the activity of
the gut microbiota were monitored 3x/week during the baseline (d3/5/7/10/12/14) and
treatment period (d16/19/21/23/26/28/30/33/35). SCFA (acetate, propionate, and bu-
tyrate) and BCFA (isobutyrate, isovalerate, and isocaproate) were determined as described
previously [62]. Lactate production was assessed with a kit (R-Biopharm, Darmstadt,
Germany), according to the manufacturer’s instructions.
2.6. Statistical Methods
All statistical analyses were performed using GraphPad Prism version 8.2.0 (435)
for Windows (GraphPad Software, San Diego, CA, USA). All formal hypothesis tests
were conducted at the 5% significance level (α = 0.05). Comparison of data from the
control and treatment conditions on microbial metabolic and composition markers of
the five BF and five toddler donors was made by calculating the average per condition
and then by performing a two-way ANOVA with Bonferroni correction. The equality of
variance and normality of the data and residuals were checked based on visual inspection
of homoscedasticity and QQ-plots, respectively. Principal component analysis (PCA) was
performed using ClustVis (https://biit.cs.ut.ee/clustvis/ (accessed on 16 October 2020),
accessed on the 8th of May, 2020) after standardizing data [63]. Briefly, dimensions were first
centered and scaled before being uploaded in ClustVis (Metsalu, T. & Vilo, J., 2015, Nucleic
Acids Research), in order to reduce the impact of large units. Principal components were
calculated using the SVD method with imputation in pcaMethods [64] R package, which
performs imputation and Singular Value Decomposition (SVD) iteratively until estimates
of missing values converge. For the data processing, unit variance scaling method was
performed using pcaMethods R package, which divides the values by standard deviation
so that each row has variance equal to one. Variables were grouped per treatment and
sampling time, and shaped depending on the original donor.
For each microbial metabolic and growth marker (pH, Gas production, SCFA, BCFA,
lactate, and qPCR), the increase or decrease from either 0 h to 24 h or from 0 h to 48 h
of incubation was used to create a joint PCA biplot that allowed comparing the five BF
infants’ or the five toddler’s microbial changes induced by lactose or 2’-FL during the first
part of the study. Comparison of the data of the baseline, lactose and 2’-FL conditions
on microbial metabolic and composition markers of the two selected donors was made
by performing a two-way ANOVA with Bonferroni correction. The approximation of
the normal distribution of the data was assumed due to the small sample size [65], and
the homoscedasticity across the samples was checked by plotting the residuals, although
the sample size was equal.
2.7. Ethics
Fecal samples of the five BF infants and five toddlers were collected according to the
ethical approval of the University Hospital Ghent (reference number B670201836585). This
involved obtaining informed consent of legal representatives for inclusion.
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3. Results
3.1. Effect of 2’-FL versus Lactose on Microbial Activity and Bifidobacterium Levels in
Short-Term Incubations
To select representative donors for the long-term M-SHIME® study, five BF infants
(D1–D5) and five toddlers (D6–D10) were screened based on their fecal microbiota fermen-
tation of lactose and 2’-FL (versus a blank control) during 48 h incubations.
While pH changes for the control were minimal and similar among the different
donors, both lactose and 2’-FL treatment resulted in strong pH decreases (Figure 2A). There
was marked interindividual variation among the BF infant donors (D1–D5) in response to
2’-FL treatment, with no (D3) or a delayed acidification between 24–48 h (D2, D4, and D5).
As a result, lactose more strongly decreased the pH between 0–24 h compared to 2’-FL for
BF infants. After 48 h of incubation, the pH decrease was still more profound for lactose
(mostly due to D2, D3, and D4), yet, 2’-FL had also greatly decreased pH compared to the
blank at that point. In contrast to the BF infants, there was less interindividual variation in
pH changes upon lactose or 2’-FL treatment for the five toddlers (D6–D10), with rapid pH
decreases for both substrates within 24 h. As compared to BF infants, 2’-FL decreased pH
more strongly, with a greater pH decrease being noted for 2’-FL compared to lactose for each
donor, though not reaching statistical significance when averaged over the five donors.
Gas formation was minimal and similar for the control incubations of all donors
tested (Figure 2B). Upon 2’-FL treatment, the fecal microbiota of BF infants again displayed
considerable interindividual variation with no additional (D3) or a delayed gas formation
(D2, D4, and D5). In contrast, lactose resulted in a strong and immediate (within 24 h)
increase in gas production for the BF infants. As a result, overall gas production (D1–D5)
was significantly higher with lactose than with 2’-FL. Further, there was again less interindi-
vidual variation for toddlers (compared to BF infants) and as was observed for BF infants,
significantly more gas was produced with lactose versus 2’-FL treatment (Figure 2B).
Levels of individual SFCAs, lactate, BCFAs, and Bifidobacterium (16S rRNA gene
copies/mL) are shown in Figure 3. Treatment with either lactose or 2’-FL significantly
increased acetate production compared to the blank control (Figure 3A). This acetate
increase was observed for both BF infant and toddlers and was most pronounced with
2’-FL treatment in the toddler samples. Lactate production was also higher with lactose
and 2’-FL treatment for both BF infant and toddler samples compared to the blank control
(Figure 3B), although not reaching statistical significance with 2’-FL treated stool microbiota
from BF infants. Lactose increased lactate production consistently in all BF infant samples,
while 2’FL did not. Compared to blank controls, both propionate and butyrate production
showed a slight increase that did not reach statistical significance with 2’-FL, but not with
lactose for BF infant samples. Propionate was significantly higher for toddler samples
treated with 2’-FL, but not with lactose, compared to blank controls (Figure 3C). Apparent
butyrate production changes by either lactose or 2’-FL treatment for BF infant or toddler
samples did not reach statistical significance (Figure 3D). Under all conditions and for all
but one BF infant samples, BCFA production was very low. Toddler samples produced
the highest BCFA levels in the blank control samples, while significantly lower amounts
were produced with both the lactose and 2’-FL treatments (Figure 3E). There was an overall
tendency for lactose and 2’-FL treatment to increase the levels of Bifidobacterium compared
to the blank control that reached significance for the toddler simulation. In the BF infant
samples, a relatively high variability in the individual donor responses was observed,
with several samples that seemingly did not respond to 2’-FL with increased growth of
the Bifidobacterium population (Figure 3F). This contrasts the observed acetate response, a
typical Bifidobacterium metabolite, of almost all BF infant samples to 2’-FL (Figure 3A).
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Figure 2. Effect of lactose or 2’-FL on fermentation parameters in short-term colonic incubations. Bars represent changes in
(A) pH and (B) gas formation during two time intervals (0–24 h and 24–48 h) of 48 h fecal batch incubations for five BF
infants (D1, D2, D3, D4, and D5) and five toddlers (D6, D7, D8, D9, and D10), upon treatment with lactose or 2’-FL versus a
blank control. Besides presenting the data for each donor separately, the average and standard deviation within age group
is also presented (D1–5; D6–10). BF = breastfed; 2’-FL = 2’fucosyllactose; D = donor. Significant differences between the
average control and the two treatments per age group, as tested with a two-way ANOVA with Bonferroni correction, are
indicated with different letters (0-24 h: a, b; 24-48 h: A, B; p <0.05).
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Figure 3. Effect of lactose or 2’-FL on bacterial metabolites and Bifidobacterium levels in short-term colonic incubations. Bars
represent changes in (A) acetate, (B) lactate, (C) propionate, (D) butyrate, (E) BCFA, and (F) Bifidobacterium levels during
short-term fecal batch incubations (0–48 h) for five breastfed (BF) infants (D1, D2, D3, D4, and D5) and five toddlers (D6,
D7, D8, D9, and D10), upon treatment with lactose or 2’-FL versus a blank control (n = 5, 1 each from 5 individual donors).
BF = breastfed; 2’-FL = 2’fucosyllactose; D = donor; BCFA = branched-chain fatty acids; SCFA = short-chain fatty acids.
Significant differences between the average control and the two treatments per age group, as tested with a two-way ANOVA
with Bonferroni correction, are indicated with different letters (a, b, c; p <0.05).
The overall effects of the lactose and 2’-FL treatments on metabolic markers (pH, Gas,
SCFA, BCFA, and lactate) and Bifidobacterium levels (at 24 and 48 h) were visualized in
a single plot using PCA (Figure 4). This illustrates that the interindividual differences
among donor samples were more pronounced for BF infants than for toddlers. Despite this,
there were several consistent findings. First, lactose exerted an immediate treatment effect
(within 24 h) that was stable at 48 h for both BF infant and toddler samples. Then, treatment
with 2’-FL differed from lactose as the samples clustered in a different region. Moreover,
the effect of 2’-FL treatment was more delayed, particularly for BF infant samples. D5 (BF
infant) and D10 (toddler) were chosen for a more in-depth M-SHIME® study, as they fell in
the middle of the 95% confidence intervals for treatment effects of both lactose and 2’-FL.
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Figure 4. Effect of lactose or 2’-FL on microbial activity and Bifidobacterium populations short-term colonic incubations.
Principal component analysis (PCA) plots for (A) BF infant fecal samples (n = 5, 1 each from 5 individual donors) and (B)
toddler fecal samples (n = 5, 1 each from 5 individual donors) representing metabolic data (pH, Gas, SCFA, BCFA, and
lactate) and Bifidobacterium levels obtained for blank control, lactose, or 2’-FL treatments after 24 h and 48 h. Ellipses indicate
clusters identified after automatic classification based on PCA scores at 95% confidence interval. BCFA, branched-chain
fatty acid; BF = breastfed; 2’-FL = 2’fucosyllactose; D = donor; PC = principal component; SCFA, short-chain fatty acid.
3.2. Long-Term M-SHIME® Study
3.2.1. Microbial Composition in the M-SHIME® Model Simulating a BF Infant or Toddler
Stool Sample
To gain insight into the overall microbial colonization of the M-SHIME® model for both
the BF infant and toddler simulation, family-level data was averaged over all study arms
and along the entire experiment (d14, d16, d26, and d35), and compared to the composition
of the original inocula (Table S1). This revealed that 4–7 weeks after inoculation, almost all
families present in the original inocula were still present in the M- SHIME® model, thus
confirming that this in vitro model was able to maintain a large part of the bacterial taxa
of the inocula. This included the maintenance of the high levels of Bifidobacteriaceae that
was an abundant group in the inocula of the BF infant and toddler under investigation.
Further, the toddler M-SHIME® was colonized by considerable levels of Bacteroidaceae,
Lachnospiraceae, and Ruminococcaceae that were also part of the toddler inoculum. As a
remark, Veillonellaceae were overrepresented in samples derived from the in vitro model.
Finally, significant differences in relative abundance between the proximal and distal
colon (indicated in bold i Table S1), and b tween the luminal and mucosal compartments
(i icated in italic i Tabl S1), highlight intrinsic differences in the microbi l communities
in each of these four regions. As an example, Bacteroidaceae were enriched in the lu nal
environ ent of the toddler simulation eaching abundances of around 12% in the lum
and between 3.64–5.11% in mucus.
3.2.2. Effect of Repeated Administration of 2’-FL versus Lactose on Microbial Composition
in the M-SHIME®
The ffects of lactose or 2’-FL treatment on the BF infant and toddler microbial com-
munity composition at phylum level are shown in Figure 5, while changes at the family
level are shown in Table 1 and Table S2–S4 for the lumen of the proximal or distal colon as
well as the mucus of the proximal or distal colon. First, in the lumen of the proximal colon
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2’-FL immediately increased Actinobacteria (from d14 to d16), both for the BF infant and
toddler simulations. This was due to a marked stimulation of Bifidobacteriaceae by 2’-FL
from d14 to d16 from 6.5 and 12.9% up to 38.2 and 46.6% for both the BF infant and toddler
samples. This immediate bifidogenic effect in the lumen of the proximal colon was not
observed upon lactose treatment for the BF infant sample, while it was observed, albeit to a
milder extent, for the toddler sample with an increase from 10 to 27% in relative abundance.
Repeated administration of lactose resulted in more pronounced bifidogenic effects on d26
and d35. Overall, the treatment effects in the lumen of the distal colon and in the mucus of
the proximal and distal colon were similar to those observed for the lumen of the proximal
colon, although there were minor differences that are likely due to intrinsic variation in the
microbial community composition in each environment. Notably, the relative abundance
of the Veillonellaceae family was reduced after treatment with 2’-FL, but not with lactose,
both for the BF infant and toddler. This effect was less pronounced in the mucus compared
with the lumen.
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Figure 5. Effect of long-term administration of lactose or 2’-FL on infant and todder microbiota in vitro. Stacked bars
represent proportional abundance at the phylu level ( ) for BF infant or toddler microbiota before (d14) and after
treatment with lactose or 2’-FL (d16, d26, and ) i t - I ®: ( ) l en, (B) DC lumen, (C) PC mucus, (D) DC
mucus. BF = breastfed; 2’-FL = 2’fucosyllactose; d = day; PC = proximal colon; DC = distal colon; M-SHIME® = mucosal
simulator of the human intestinal microbial ecosystem. Arrows indicate the start of treatment with lactose or 2’-FL.
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Table 1. Proportional composition at the family level (%) as determined via 16S-targeted Illumina sequencing in the lumen of the proximal colon of the M-SHIME® inoculated with BF
infant or toddler fecal samples (before [d14] and after [d16, d26, and d35] treatment with lactose or 2’-FL) (n = 1).
Phylum Family
BF Infant Toddler
Lactose 2’-FL Lactose 2’-FL
d14 d16 d26 d35 d14 d16 d26 d35 d14 d16 d26 d35 d14 d16 d26 d35
Actinobacteria
Atopobiaceae - - - - - - - - - - - - - - 0.03 0.23
Bifidobacteriaceae 5.40 8.24 4.42 17.02 6.55 38.20 38.40 35.21 10.04 27.08 46.15 47.65 12.93 46.60 55.46 57.24
Cellulomonadaceae - - - - - - - - - - 0.26 0.13 - - 0.004 0.05
Coriobacteriaceae 0.28 0.08 0.05 0.08 0.18 0.22 0.57 0.26 0.56 0.33 2.83 1.43 1.98 5.43 3.05 8.57
Eggerthellaceae - - - - - - - - - - - 0.02 0.01 - 0.004 0.003
Microbacteriaceae - - - - - - - - 0.003 0.01 0.02 0.01 - - - 0.06
Bacteroidetes
Bacteroidaceae 1.39 6.74 0.56 1.15 2.35 1.45 1.37 0.84 15.13 4.07 11.74 13.14 21.16 4.55 10.63 14.50
Marinifilaceae - - - - - - - - - - - - - - - -
Porphyromonadaceae 0.09 0.35 0.24 0.31 0.29 0.16 0.23 0.24 - - - - - - - -
Rikenellaceae 0.06 0.23 0.75 0.35 0.09 0.07 0.17 0.46 0.003 0.02 0.02 0.01 0.01 0.01 0.01 -
Tannerellaceae - - - - - - - - 0.29 0.09 0.21 0.54 0.53 0.03 0.30 0.14
Firmicutes
Acidaminococcaceae - - - - - - - - 0.07 0.14 2.27 1.56 0.37 0.21 1.50 1.20
Clostridiaceae_1 0.01 0.02 - - 0.01 0.01 - - - 0.02 - - - - - -
Clostridiales
Incertae_Sedis_XI - 0.12 - - 0.005 0.01 - - - - - - - - - -
Clostridiales
unclassified - - - - - - - - - - - - - - - -
Erysipelotrichaceae - - - - - - - - 0.03 0.01 - 0.04 0.02 0.01 0.02 0.02
Eubacteriaceae - - - - - - - - 0.01 - 0.00 0.04 0.02 0.01 - 0.01
Lachnospiraceae 4.32 14.97 27.30 9.97 4.40 26.59 7.67 10.99 49.78 24.91 5.12 11.37 36.15 14.58 10.51 4.47
Lactobacillaceae - - - - - - - - - - 0.01 0.01 - - - -
Ruminococcaceae 0.39 1.34 0.30 0.60 0.85 0.20 0.09 0.17 0.10 0.04 0.01 9.67 0.04 - 0.04 0.37




Lactose 2’-FL Lactose 2’-FL
d14 d16 d26 d35 d14 d16 d26 d35 d14 d16 d26 d35 d14 d16 d26 d35
Streptococcaceae - - - - - - - - - - - - - - - -
Veillonellaceae 87.81 67.41 65.99 69.76 84.71 32.66 50.62 51.33 22.00 42.32 30.33 12.32 24.76 27.61 17.00 12.20
Proteobacteria
Burkholderiaceae - - - - - - - - 0.22 0.04 0.16 0.33 0.08 - 0.12 0.34
Campylobacteraceae - - - - - - - - - - - - - - - -
Desulfovibrionaceae - - - - - - - - 0.16 0.14 0.02 0.02 0.11 0.03 0.07 0.02
Enterobacteriaceae 0.03 0.01 0.01 0.26 0.05 0.01 0.14 0.09 1.31 0.64 0.71 1.18 1.63 0.84 1.14 0.53
Pseudomonadaceae 0.06 0.11 0.24 0.29 0.09 0.08 0.41 0.15 0.16 0.11 0.11 0.07 0.03 0.01 0.08 0.04
Sutterellaceae 0.06 0.10 0.07 0.14 0.20 0.09 0.25 0.18 - - - - - - - -
Xanthomonadaceae 0.02 0.04 0.03 - 0.05 0.06 0.03 0.01 0.11 0.003 0.01 0.40 0.08 0.01 0.01 0.01
Verrucomicrobia Akkermansiaceae - - - - - - - - - - - 0.01 - - - -
M-SHIME® = mucosal simulator of the human intestinal microbial ecosystem; BF = breastfed; d = day; 2’-FL = 2’fucosyllactose.
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3.2.3. Effect of Repeated Administration of 2’-FL versus Lactose on Microbial Activity in
the M-SHIME®
First, lactose and 2’-FL increased gas production both for the BF infant and toddler
sample, with the increase being significantly higher with lactose compared to 2’-FL, con-
sistent with the findings from the short term donor screening (part 1) (Figure S1A). For
the BF infant sample, lower gas production for 2’-FL as compared to lactose seemed to be
specifically related to lower H2 levels (Figure S1B). Also, for the toddler sample a slightly
lower H2 level was observed upon 2’-FL treatment compared to lactose. For the toddler,
a peculiar finding was that repeated administration between d14 and d35 resulted in
lower gas production upon exposure to lactose and 2’-FL treatments compared to baseline.
This likely resulted from lower H2 production for lactose and especially 2’-FL, while CO2
levels also decreased for lactose.
The levels of SCFAs and BCFAs were stable during the baseline period in both the
proximal (Figure 6) and distal (Figure S2) colon. In the proximal colon, treatment with both
lactose and 2’-FL significantly increased acetate production compared to baseline for both
BF infant and toddler microbiota; the increase was greater for 2’-FL when averaged over
the entire treatment period (Figure 7A). The time-course data for 2’-FL (Figure 6B,D) high-
lighted that 2’-FL immediately and strongly increased acetate from the start of the treatment.
As acetate is a key metabolite of Bifidobacteriaceae members, this correlates with the strong
effect of 2’-FL on the relative abundance of this taxonomic group. Propionate levels sig-
nificantly increased after both lactose and 2’-FL treatment for the BF infant microbiota,
with the increase being greater with lactose compared to 2’-FL (Figure 7B). This finding
correlates with the higher levels of the propionate producing Veillonellaceae family for
lactose compared to 2’-FL (Figure 7B). In contrast, the toddler microbiota produced very
little propionate at baseline and production did not increase with either lactose or 2’-FL
treatment. Butyrate production significantly increased after treatment with either lactose
or 2’-FL for both the BF infant and toddler microbiota. For the toddler microbiota, the
increase was more pronounced with lactose versus 2’-FL (Figure 7C). In the distal colon,
similar treatment effects on acetate (Figure S3A), propionate (Figure S3B), and butyrate
(Figure S3C) were observed. Lactate levels were very low in both the proximal and distal
colon regardless of the treatment, indicating a good conversion of this intermediate. Fi-
nally, compared to baseline, BCFA production was significantly decreased after treatment
with either lactose or 2’-FL for both the BF infant and toddler microbiota in the proximal
(Figure 7D) and distal (Figure S3D) colon lumen. No differences were observed in alpha
diversity indices (Shannon, Chao1), richness or evenness after lactose or 2’-FL treatment
(Supplementary Figure S4).
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4. Discussion
The current study combined two distinct in vitro gut odels to address the effect
of 2’-FL on the gut icrobio e of BF infants and toddlers using lactose as a comparator.
First, short-term fecal batch incubations were applied as they allow to more cost-effectively
include the aspect of inter-individual variability among donors. This revealed that the BF
infant population was characterized by larger inter-individual variations, particularly in
terms of 2’-FL fermentation. These data correspond with in vivo findings demonstrating
that only some infants have Bifidobacterium strains that can use 2’FL [26]. The combined
comparison of all read-outs from the first screening by PCA allowed for the selection of a
representative donor for each age group for an in-depth study using the M-SHIME® model.
This facilitated focus on additional research questions, such as the effect of repeated intake
of 2’-FL, the longitudinal effects along the proximal and distal colon and the effects on
the luminal and mucosal microbiota. While an M-SHIME® simulation for 3-month old
infants was previously developed [47], this is the first report where we demonstrated a
stable and diverse microbiota in the toddler M-SHIME® model. The microbial composition
of the toddler M-SHIME® after the 14d stabilization period was, like for the BF infant
simulation, similar to that of the inoculum in both the lumen and mucus of the proximal
and distal colon compartments, with almost all of the families present in the inoculum
being represented in the toddler M-SHIME®.
In these investigations, 2’-FL fermentation had an immediate and strong bifidogenic
effect as demonstrated by the increased relative Bifidobacteriaceae abundance from d14 to
d16 for both the BF infant and toddler microbiota. Lactose fermentation resulted in a less
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immediate bifidogenic effect for the toddler microbiota and did not increase Bifidobacteri-
aceae during the first two treatment weeks for the BF infant microbiota. Bifidobacteria are
considered beneficial for human health, and low abundance is linked to gastrointestinal
and metabolic diseases [66]. A loss of Bifidobacterium species during the early colonization
of the infant gut can alter the normal progression of the gut microbial community and
may negatively impact host health [67]. Therefore, 2’-FL may have a long-term impact on
infant and toddler health by potentially increasing the relative abundance of bifidobacteria,
and especially their metabolic activity seen in the formation of acetate. Moreover, it is
plausible 2’-FL can maintain bifidobacteria presence and activity within the gut microbial
community during the diversification of the gut microbiota following the introduction of
a complementary diet. Supporting the growth and metabolic activity of Bifidobacteriaceae
members seems important since many members have been associated with health benefits
for the host [68,69].
Additional evidence that the Bifidobacteriaceae were a major group of bacteria involved
in the fermentation of 2’-FL followed from the observation that acetate, a major metabolite
of Bifidobacteriaceae [70], was consistently produced at a higher level upon 2’-FL treatment
in BF infant and toddler samples in both model systems. These findings are in agreement
with a study of the effect of 2’-FL on in vitro colon simulations using infant fecal samples
that reported increased acetate production with 2’-FL [71]. Interestingly, acetate has been
shown to have immune protective effects both for gastrointestinal pathogens in preclinical
in vivo models [72,73]. Hence, 2’FL stimulated the metabolic activity of the microbiota
may have important physiologic effects on infant and toddler health.
Another observation that suggests the involvement of Bifidobacteriaceae in the fermen-
tation of 2’-FL is linked to the measured gas formation. Fermentation of 2’-FL and lactose
resulted in similar acidification. However, only lactose treatment resulted in a strong
increase in gas formation. The lower gas production with 2’-FL compared to lactose was
consistently observed for BF infants and toddlers in both models. The long-term M-SHIME®
model allowed for the conclusion that the observed decrease with 2’-FL was primarily due
to H2. While fermentation of glycans by colonic microbes usually results in gas production
and acidification, fermentation by Bifidobacteriaceae results in acidification without gas
production, as Bifidobacteriaceae do not produce gases [74,75]. This seems to be consistent
with in vivo observations for adults, who only experienced mild gas production with 2’-FL
as a supplement up to 20 g per day compared to a placebo control [38]. Irrespective of
the hypothesis on the involvement of Bifidobacteriaceae, the consistently observed mild gas
production with 2’-FL is of great interest as it indicates breast milk components like 2’-FL
may counterbalance the gas-forming fermentation of other components such as lactose.
This may lead to less gut discomfort. Noteworthy, for the toddler M-SHIME® study, we
observed that repeated administration of 2’-FL or lactose resulted in lower gas production.
This suggests that long-term administration leads to metabolic adaptation and a shift in the
ecosystem. To what extent this finding could translate to counterbalance gastrointestinal
discomfort symptoms in toddlers deserves further investigation.
Repeated administration of 2’-FL significantly increased production of both butyrate
and propionate versus baseline in the BF infant M-SHIME® simulation. For the toddler
simulation, there was an immediate and significant increase in butyrate, with no change in
propionate production. At the same time, BCFA production was significantly decreased
in both the BF infant and toddler simulations. Lactose treatment had similar effects.
The increases in butyrate and propionate are noteworthy because both are associated
with health benefits. Butyrate is important to colonic health as it is a preferred substrate
for colonocytes and is attributed to promoting a normal phenotype and regulating en-
ergy metabolism in these cells [76,77]. Butyrate is involved in the regulation of nitrate
by colonocytes and limits the bioavailability of luminal oxygen, which together prevent
the expansion of potentially pathogenic Escherichia and Salmonella [78]. Additionally, it is
reported to have anti-inflammatory and anti-cancer properties, contributing to increased
resistance to enteropathogens and respiratory infections, and playing a role in mitigating
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weight gain and improving insulin sensitivity [79–81]. Propionate has also been shown
to have anti-inflammatory and anti-cancer properties, and to reduce lipidogenesis and
serum cholesterol, preventing weight gain, improve insulin resistance, protect from hyper-
tensive cardiovascular damage, and to limit the growth of potentially pathogenic bacteria
such as Salmonella [82]. Additionally, SCFAs may play a role in protecting against food
allergies and allergic asthma [83–85]. The fact that butyrate and propionate, which can
exert important health benefits, were increased with 2’-FL demonstrates that dietary 2’-FL
may provide beneficial effects to both infants and toddlers.
With respect to using lactose as a comparator, it has to be noted that in individuals
who are able to digest lactose (normolactasia), only a small percentage of lactose reaches
the colon because the majority of it is absorbed in the small intestine [86]. HMOs, in
contrast, are not absorbed in the upper gastrointestinal tract where only 1–2% are absorbed
in infants [87,88]. Given this, even if the benefits of 2’-FL and lactose were equal, one would
need an approximately 50× higher dose of lactose than 2’-FL to achieve the same effects.
Therefore, 2’-FL has a distinct advantage over lactose in regard to the dose.
5. Conclusions
Data obtained using the M-SHIME® model showed a more pronounced bifidogenic
effect for both BF infant and toddler gut microbiota with 2’-FL treatment as compared
to lactose, which resulted in less gas production and more SCFA production, primarily
acetate. The relative abundance of Bifidobacteriaceae family increased with both lactose
and 2’-FL treatment for the toddler microbiota (albeit more delayed for lactose), but only
increased with 2’-FL treatment and not lactose for the BF infant microbiota. Similarly, the
screening study showed stimulated metabolic activity most likely related to bifidobacteria.
The observations made with the short- and long-term fermentation models of infant and
toddler gut microbiota reveal possible roles of 2’-FL mediated through the gut microbiota
that may contribute to infant and toddler health and wellbeing.
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CNCM I-3446 and Bovine Milk-Derived Oligosaccharides on Infant Gut Microbiota. Nutrients 2020, 12, 2268. [CrossRef]
47. Abbeele, P.V.D.; Duysburgh, C.; Vazquez, E.; Chow, J.; Buck, R.; Marzorati, M. 2′-Fucosyllactose alters the composition and
activity of gut microbiota from formula-fed infants receiving complementary feeding in a validated intestinal model. J. Funct.
Foods 2019, 61, 103484. [CrossRef]
48. de Boever, P.; Wouters, R.; Vermeirssen, V.; Boon, N.; Verstraete, W. Development of a Six-Stage Culture System for Simulating the
Gastrointestinal Microbiota of Weaned Infants. Microb. Ecol. Health Dis. 2001, 13, 111–123. [CrossRef]
49. Abbeele, P.V.D.; Belzer, C.; Goossens, M.; Kleerebezem, M.; De Vos, W.M.; Thas, O.; De Weirdt, R.; Kerckhof, F.-M.; Van De Wiele,
T. Butyrate-producing Clostridium cluster XIVa species specifically colonize mucins in an in vitro gut model. ISME J. 2013, 7,
949–961. [CrossRef] [PubMed]
50. Boon, N.; Top, E.M.; Verstraete, W.; Siciliano, S.D. Bioaugmentation as a Tool To Protect the Structure and Function of an
Activated-Sludge Microbial Community against a 3-Chloroaniline Shock Load. Appl. Environ. Microbiol. 2003, 69, 1511–1520.
[CrossRef]
51. Duysburgh, C.; Abbeele, P.V.D.; Krishnan, K.; Bayne, T.F.; Marzorati, M. A synbiotic concept containing spore-forming Bacillus
strains and a prebiotic fiber blend consistently enhanced metabolic activity by modulation of the gut microbiome in vitro. Int. J.
Pharm. X 2019, 1, 100021. [CrossRef]
52. Rinttila, T.; Kassinen, A.; Malinen, E.; Krogius, L.; Palva, A. Development of an extensive set of 16S rDNA-targeted primers for
quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J. Appl. Microbiol. 2004, 97, 1166–1177.
[CrossRef] [PubMed]
53. Klindworth, A.; Pruesse, E.; Schweer, T.; Peplies, J.; Quast, C.; Horn, M.; Glöckner, F.O. Evaluation of general 16S ribosomal
RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. Nucleic Acids Res. 2012, 41, e1.
[CrossRef]
54. De Paepe, K.; Kerckhof, F.; Verspreet, J.; Courtin, C.M.; Van De Wiele, T. Inter-individual differences determine the outcome of
wheat bran colonization by the human gut microbiome. Environ. Microbiol. 2017, 19, 3251–3267. [CrossRef] [PubMed]
55. Quast, C.; Pruesse, E.; Yilmaz, P.; Gerken, J.; Schweer, T.; Yarza, P.; Peplies, J.; Glöckner, F.O. The SILVA Ribosomal RNA Gene
Database Project: Improved Data Processing and Web-Based Tools. Nucleic Acids Res. 2013, 41, D590–D596. [CrossRef]
56. Edgar, R.C.; Haas, B.J.; Clemente, J.C.; Quince, C.; Knight, R. UCHIME Improves Sensitivity and Speed of Chimera Detection.
Bioinformatics 2011, 27, 2194–2200. [CrossRef] [PubMed]
57. Schloss, P.D.; Westcott, S.L.; Ryabin, T.; Hall, J.R.; Hartmann, M.; Hollister, E.B.; Lesniewski, R.A.; Oakley, B.B.; Parks, D.H.;
Robinson, C.J.; et al. Introducing mothur: Open-Source, Platform-Independent, Community-Supported Software for Describing
and Comparing Microbial Communities. Appl. Environ. Microbiol. 2009, 75, 7537–7541. [CrossRef]
58. Schloss, P.D.; Westcott, S.L. Assessing and Improving Methods Used in Operational Taxonomic Unit-Based Approaches for 16S
rRNA Gene Sequence Analysis. Appl. Environ. Microbiol. 2011, 77, 3219–3226. [CrossRef] [PubMed]
59. Wang, X.; Cai, Y.; Sun, Y.; Knight, R.; Mai, V. Secondary structure information does not improve OTU assignment for partial 16s
rRNA sequences. ISME J. 2011, 6, 1277–1280. [CrossRef] [PubMed]
60. Chen, W.; Zhang, C.K.; Cheng, Y.; Zhang, S.; Zhao, h. A Comparison of Methods for Clustering 16S rRNA Sequences into OTUs.
PLoS ONE 2013, 8, e70837. [CrossRef] [PubMed]
61. Zakrzewski, M.; Proietti, C.; Ellis, J.J.; Hasan, S.; Brion, M.-J.; Berger, B.; Krause, L. Calypso: A user-friendly web-server for
mining and visualizing microbiome–environment interactions. Bioinformatics 2016, 33, 782–783. [CrossRef] [PubMed]
62. Ghyselinck, J.; Verstrepen, L.; Moens, F.; Abbeele, P.V.D.; Said, J.; Smith, B.; Bjarnason, I.; Basit, A.W.; Gaisford, S. A 4-strain
probiotic supplement influences gut microbiota composition and gut wall function in patients with ulcerative colitis. Int. J. Pharm.
2020, 587, 119648. [CrossRef] [PubMed]
63. Metsalu, T.; Vilo, J. ClustVis: A web tool for visualizing clustering of multivariate data using Principal Component Analysis
and heatmap. Nucleic Acids Res. 2015, 43, W566–W570. [CrossRef] [PubMed]
64. Stacklies, W.; Redestig.; H Scholz, M.; Walther, D.; Selbig, J. pcaMethods a bioconductor package providing PCA methods for
incomplete data. Bioinformatics 2007, 23, 1164–1167. [CrossRef] [PubMed]
65. Öztuna, D.; Elhan, A.; Tüccar, E. Investigation of four different normality tests in terms of type 1 error rate and power under
different distributions. Turk. J. Med. Sci. 2006, 36, 171–176.
66. Lê, K.-A.; Li, Y.; Xu, X.; Yang, W.; Liu, T.; Zhao, X.; Tang, Y.G.; Cai, D.H.; Go, V.L.W.; Pandol, S.; et al. Alterations in fecal
Lactobacillus and Bifidobacterium species in type 2 diabetic patients in Southern China population. Front. Physiol. 2013, 3, 496.
[CrossRef] [PubMed]
67. Wampach, L.; Heintz-Buschart, A.; Fritz, J.V.; Ramiro-Garcia, J.; Habier, J.; Herold, M.; Narayanasamy, S.; Kaysen, A.; Hogan,
A.H.; Bindl, L.; et al. Birth mode is associated with earliest strain-conferred gut microbiome functions and immunostimulatory
potential. Nat. Commun. 2018, 9, 1–14. [CrossRef]
68. O’Callaghan, A.; Van Sinderen, D. Bifidobacteria and Their Role as Members of the human Gut Microbiota. Front. Microbiol. 2016,
7, 925. [CrossRef]
Nutrients 2021, 13, 726 22 of 22
69. Laursen, M.; Sakanaka, M.; von Burg, N.; Andersen, D.; Mörbe, U.; Rivollier, A.; Pekmez, C.; Moll, J.; Michaelsen, K.; Mølgaard,
C.; et al. Breastmilk-promoted bifidobacteria produce aromatic lactic acids in the infant gut. bioRxiv 2020. [CrossRef]
70. Bunesova, V.; Lacroix, C.; Schwab, C. Fucosyllactose and L-fucose utilization of infant Bifidobacterium longum and Bifidobac-
terium kashiwanohense. BMC Microbiol. 2016, 16, 1–12. [CrossRef]
71. Salli, K.; Anglenius.; H Hirvonen, J.; Hibberd, A.A.; Ahonen, I.; Saarinen, M.T.; Tiihonen, K.; Maukonen, J.; Ouwehand, A.C. The
effect of 2′-fucosyllactose on simulated infant gut microbiome and metabolites; a pilot study in comparison to GOS and lactose.
Sci. Rep. 2019, 9, 1–15. [CrossRef]
72. Fukuda, S.; Toh.; H Hase, K.; Oshima, K.; Nakanishi, Y.; Yoshimura, K.; Tobe, T.; Clarke, J.M.; Topping, D.L.; Suzuki, T.; et al.
Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 2011, 469, 543–547. [CrossRef]
73. Antunes, K.H.; Fachi, J.L.; De Paula, R.; Da Silva, E.F.; Pral, L.P.; Dos Santos, A.Á.; Dias, G.B.M.; Vargas, J.E.; Puga, R.; Mayer,
F.Q.; et al. Microbiota-derived acetate protects against respiratory syncytial virus infection through a GPR43-type 1 interferon
response. Nat. Commun. 2019, 10, 1–17. [CrossRef]
74. Bernalier, A.; Dore, J.; Durand, M. Biochemistry of Fermentation. In Colonic Microbiota, Nutrition and Health; Springer International
Publishing: Berlin/Heidelberg, Germany, 1999; pp. 37–53.
75. Falony, G.; Verschaeren, A.; De Bruycker, F.; De Preter, V.; Verbeke, K.; Leroy, F.; De Vuyst, L. In Vitro Kinetics of Prebiotic
Inulin-Type Fructan Fermentation by Butyrate-Producing Colon Bacteria: Implementation of Online Gas Chromatography for
Quantitative Analysis of Carbon Dioxide and Hydrogen Gas Production. Appl. Environ. Microbiol. 2009, 75, 5884–5892. [CrossRef]
[PubMed]
76. Topping, D.L.; Clifton, P.M. Short-Chain Fatty Acids and Human Colonic Function: Roles of Resistant Starch and Nonstarch
Polysaccharides. Physiol. Rev. 2001, 81, 1031–1064. [CrossRef] [PubMed]
77. Donohoe, D.R.; Garge, N.; Zhang, X.; Sun, W.; O’Connell, T.M.; Bunger, M.K.; Bultman, S.J. The Microbiome and Butyrate
Regulate Energy Metabolism and Autophagy in the Mammalian Colon. Cell Metab. 2011, 13, 517–526. [CrossRef]
78. Byndloss, M.X.; Olsan, E.E.; Rivera-Chávez, F.; Tiffany, C.R.; Cevallos, S.A.; Lokken, K.L.; Torres, T.P.; Byndloss, A.J.; Faber, F.;
Gao, Y.; et al. Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion. Science 2017, 357, 570–575.
[CrossRef]
79. Hamer.; H Jonkers, D.; Venema, K.; Vanhoutvin, S.; Troost, F.J.; Brummer, R. Review article: The role of butyrate on colonic
function. Aliment. Pharmacol. Ther. 2007, 27, 104–119. [CrossRef] [PubMed]
80. Gao, Z.; Yin, J.; Zhang, J.; Ward, R.E.; Martin, R.J.; Lefevre, M.; Cefalu, W.T.; Ye, J. Butyrate Improves Insulin Sensitivity and
Increases Energy Expenditure in Mice. Diabetes 2009, 58, 1509–1517. [CrossRef] [PubMed]
81. Vinolo, M.A.; Rodrigues, h.G.; Nachbar, R.T.; Curi, R. Regulation of inflammation by short chain fatty acids. Nutrients 2011, 3,
858–876. [CrossRef]
82. Chambers, E.S.; Viardot, A.; Psichas, A.; Morrison, D.J.; Murphy, K.G.; Zac-Varghese, S.E.K.; MacDougall, K.; Preston, T.; Tedford,
C.; Finlayson, G.S.; et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight
maintenance and adiposity in overweight adults. Gut 2014, 64, 1744–1754. [CrossRef]
83. Tan, J.; McKenzie, C.; Vuillermin, P.J.; Goverse, G.; Vinuesa, C.G.; Mebius, R.E.; Macia, L.; Mackay, C.R. Dietary Fiber and Bacterial
SCFA Enhance Oral Tolerance and Protect against Food Allergy through Diverse Cellular Pathways. Cell Rep. 2016, 15, 2809–2824.
[CrossRef]
84. Cait, A.; Hughes, M.R.; Antignano, F.; Cait, J.; Dimitriu, P.; Maas, K.R.; Reynolds, L.; Hacker, L.; Mohr, J.; Finlay, B.B.; et al.
Microbiome-driven allergic lung inflammation is ameliorated by short-chain fatty acids. Mucosal Immunol. 2018, 11, 785–795.
[CrossRef] [PubMed]
85. Trompette, A.; Gollwitzer, E.S.; Yadava, K.; Sichelstiel, A.K.; Sprenger, N.; Ngom-Bru, C.; Blanchard, C.; Junt, T.; Nicod, L.P.;
Harris, N.L.; et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med.
2014, 20, 159–166. [CrossRef] [PubMed]
86. Bond, J.H.; Levitt, M.D. Quantitative Measurement of Lactose Absorption. Gastroenterology 1976, 70, 1058–1062. [CrossRef]
87. Bruggencate, S.J.M.T.; Bovee-Oudenhoven, I.M.J.; Feitsma, A.L.; Van Hoffen, E.; Schoterman, M.H.C. Functional role and
mechanisms of sialyllactose and other sialylated milk oligosaccharides. Nutr. Rev. 2014, 72, 377–389. [CrossRef] [PubMed]
88. Rudloff, S.; Obermeier, S.; Borsch, C.; Pohlentz, G.; Hartmann, R.; Brösicke.; H Lentze, M.J.; Kunz, C. Incorporation of orally
applied 13C-galactose into milk lactose and oligosaccharides. Glycobiology 2006, 16, 477–487. [CrossRef] [PubMed]
